Business Context and Reporting Period
Company: China Pharma Holdings, Inc. (CPHI)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2024
Operations: The Company operates through its wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., in the People's Republic of China (PRC). It develops, manufactures, and markets pharmaceutical products (injectables, tablets, capsules) and is exploring nutrition products and comprehensive healthcare solutions.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2024 | Nine Months Ended Sept 30, 2024 |
|---|---|---|
| Revenue | $1.10 million | $3.39 million |
| Cost of Revenue | $1.62 million | $5.22 million |
| Gross Loss | $(0.52) million | $(1.83) million |
| Net Loss | $(1.12) million | $(3.51) million |
| Loss Per Share (Basic/Diluted) | $(0.06) | $(0.23) |
| Cash and Cash Equivalents | $0.72 million | $0.72 million (as of Sept 30) |
| Total Assets | $13.47 million | $13.47 million (as of Sept 30) |
| Total Liabilities | $6.94 million | $6.94 million (as of Sept 30) |
| Stockholders' Equity | $6.53 million | $6.53 million (as of Sept 30) |
Liquidity: Cash and cash equivalents decreased from $1.42 million at year-end 2023 to $0.72 million at September 30, 2024. The Company has a working capital deficit of approximately $1.0 million (Current Liabilities exceed Current Assets).
Material Changes vs. Prior Period
- Revenue Decline: Revenue for the nine months ended September 30, 2024, decreased 30% to $3.39 million from $4.86 million in the prior year. The decline was driven by a 91% drop in "Digestive Diseases" sales (Omeprazole demand normalization) and a 73% drop in "Other" products (Vitamin B6) due to centralized procurement policies.
- Worsening Margins: The Company reported a gross loss of $1.83 million (53.8% margin) for the nine months ended September 30, 2024, compared to a gross loss of $0.20 million (4.2% margin) in the prior year. This was caused by reduced revenue volume leading to higher idle equipment costs and inventory impairments.
- Increased Expenses: General and administrative expenses rose due to amortization of newly acquired intangible assets (technology transfer agreements). R&D expenses increased by 206% year-over-year due to costs associated with drug consistency evaluations.
- Accounts Receivable: Gross accounts receivable remain high at $14.27 million, with an allowance for doubtful accounts of $13.94 million (97.7% of gross). Approximately 97.8% of gross receivables are aged over 720 days.
Outlook, Risks, and Contingencies
- Going Concern Warning: Management has disclosed substantial doubt about the Company's ability to continue as a going concern within one year. This is due to accumulated deficits of $42.8 million, recurring net losses, and negative operating cash flows. The Company relies on advances from the CEO/Chairman ($1.17 million) and existing lines of credit.
- Convertible Note: The Company has a convertible note payable to Streeterville Capital, LLC. The maturity was extended to August 19, 2025. The investor has been converting portions of the note into common stock at a discount (82% of VWAP), resulting in significant share issuance (over 4.2 million shares issued in 2024 to date).
- Regulatory Environment: Operations are heavily impacted by China's Centralized Procurement (CP) policies, which reduce drug prices. The Company is balancing the cost of "consistency evaluation" required to participate in CP against the potential market access.
- Internal Controls: The Company disclosed a material weakness in internal controls over financial reporting due to a lack of personnel knowledgeable in U.S. GAAP. Disclosure controls were deemed ineffective.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $0.72 million cash balance against the $1.0 million working capital deficit and ongoing operating losses.
- Receivables Quality: Assess the recoverability of the $14.27 million gross accounts receivable, noting that 97.8% is aged over 720 days and nearly fully reserved.
- Dilution Risk: Monitor the conversion rate of the Streeterville Capital convertible note, which continues to dilute existing shareholders as the stock price declines.
- Related Party Dependence: Confirm the sustainability of the $1.17 million in borrowings from the Chairperson/CEO required to fund operations.
- Product Pipeline: Evaluate the progress and ROI of the "consistency evaluation" projects for existing drugs to determine if they will qualify for Centralized Procurement.